abstract |
The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful for the treatment of diseases and conditions mediated by the ORL-1 receptor. To do. The present invention is further directed to processes for preparing said derivatives, pharmaceutical compositions comprising said derivatives, and methods for treating ORL-1-mediated diseases and conditions. |